PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1498345
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1498345
The global single-use bioprocessing market is projected to reach USD 34.9 billion by 2029 from USD 17.7 billion in 2024, at a CAGR of 14.5% during the forecast period of 2024 to 2029. The growth of this market can be attributed to growing adoption among CDMOs & CMOs. The growth of the single-use bioprocessing market has been significantly driven by its increasing adoption among Contract Development and Manufacturing Organizations (CDMOs) and Contract Manufacturing Organizations (CMOs). These organizations play a crucial role in the biopharmaceutical industry by offering specialized services to companies looking to outsource their drug development and manufacturing processes. This trend is expected to drive the growth of the single-use bioprocessing market in the coming years.
Scope of the Report | |
---|---|
Years Considered for the Study | 2022-2029 |
Base Year | 2023 |
Forecast Period | 2024-2029 |
Units Considered | Value (USD) |
Segments | By Product, Application, Workflow, Molecule Type, And End User |
Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
"The pharmaceutical & biotechnology companies segment accounted for the largest share by end user in 2023."
In 2023, the pharmaceutical & biotechnology companies segment accounted for the largest share by end user in the global single-use bioprocessing market. Single-use equipment decreases cross-product/batch contamination risks, increases product integrity, reduces downtime, lowers cleaning costs, decreases facility setup expenses, provides a smaller manufacturing footprint, and improves facility flexibility and adaptability. These advantages drive the adoption of single-use bioprocessing products by pharmaceutical & biopharmaceutical companies. The widespread use of single-use bioprocessing equipment and consumables in established and developed markets, such as North America and Europe, has supported market growth.
"The US has continued to dominate the single-use bioprocessing market during the forecast period of 2024-2029."
The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The demand for single-use bioprocessing products is expected to grow in the coming years, driven by the increasing focus on biopharmaceuticals, and the need for safe & high-quality products in the healthcare industry. The nation has a highly advanced market in terms of R&D due to the presence of better infrastructure, government support, and private funding. This helps develop innovative and advanced technologies for research. Pharmaceutical companies in the US are actively participating in the development of biologics and biosimilars and increasingly utilizing single-use bioprocessing, which offers less turnaround time, has low installation costs, and is energy-efficient. These factors are supporting the growth of the single-use bioprocessing market in the country.
Merck KGaA (Germany)
Sartorius AG (Germany)
Danaher Corporation (US)
Thermo Fisher Scientific, Inc. (US)
Merck KGaA (Germany)
Avantor, Inc. (US)
3M Company (US)
Repligen Corporation (US)
Entegris (US)
Getinge AB (Sweden)
Parker Hannifin Corporation (US)
Alfa Laval Corporate AB (Sweden)
Saint-Gobain (France)
Eppendorf SE (Germany)
Corning Incorporated (US)
Eaton Corporation plc (Ireland)
METTLER TOLEDO (US)
Porvair PLC (UK)
Lonza (Switzerland)
ABEC, INC. (US)
NewAge Industries (US)
PBS Biotech, Inc. (US)
Sentinel Process Systems, Inc. (US)
Meissner Filtration Products, Inc. (US)
SATAKE MultiMix Corporation (Japan)
Hamilton Company (US)
Membrane Solutions (US)
Cole-Parmer Instrument Company, LLC (US)
Distek, Inc. (US)
Esco Lifesciences Group Ltd. (US)
TECNIC Bioprocess solutions (Spain).
This research report categorizes the single-use bioprocessing market by product (equipment and consumables), by application (cell culture, filtration, purification, mixing, storage & transfer, and other applications), by workflow (upstream and downstream bioprocessing), by molecule type (monoclonal antibodies (mAbs), vaccines, therapeutic proteins & peptides, and cell & gene therapies), by end user (pharmaceutical & biotechnology companies, CMOs & CROs, and academic & research institutes) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the single-use bioprocessing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the single-use bioprocessing market.
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall single-use bioprocessing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.